CARDIAC INTERVENTION THERAPY FOR THE TREATMENT OF HEART FAILURE
Defines medical necessity and investigational indications for biventricular pacemakers/CRT with or without implantable cardioverter-defibrillator (CRT-D) for treatment of heart failure, product variations, policy guidelines, background, evidence summary, and coding guidance. Applies to Capital Blue Cross programs with benefit variations.
01/24/2025 Retirement Review: Cardiac services will be delegated to TurningPoint.
12/11/2024 Administrative Update added codes 0915T-0929T effective 1/1/2025.
06/07/2024 Consensus Review: No change to policy statement. Background and Definitions updated. References added.
09/22/2020 Consensus Review: No change to policy statement. FEP language revised. Background, Rationale and References updated. Removed codes 0674T - 0685T. Added 0418T.
06/14/2021 Minor Review: Policy statement updated to include Cardiac Contractility Modulation (CCM) Therapy. Policy Name Change. Codes added.
12/01/2021 Administrative Review: Added 0674T-0685T. Effective date 1/1/2022.
03/11/2022 Administrative Review: Added K1030. Effective date 4/1/2022.
08/03/2023 Consensus Review: No change to policy statement or intent.
03/16/2020 Consensus Review: Policy statement unchanged. References updated. Coding reviewed.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.